Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478754 | 1.00 | MELK (0.57) | MELKCYP11B2CYP11B1CYP17A1CHUK | |
| SCHEMBL28325580 | 0.98 | MELK (0.56) | MELKCYP11B2CYP11B1CYP17A1CHUK | |
| SCHEMBL1515760 | 0.92 | CYP11B2 (0.60) | MELKCYP11B2CYP11B1CYP17A1CHUK | |
| SCHEMBL25625881 | 0.82 | CYP11B2 (0.50) | MELKCYP11B2CYP11B1CYP17A1CHUK | |
| SCHEMBL2006717 | 0.80 | MELK (0.57) | MELKCYP11B2CYP11B1CYP17A1CYP19A1 | |
| Isoquinoline SCHEMBL28125940 | 0.78 | CYP11B2 (0.47) | CYP11B2CYP11B1CYP17A1CYP19A1NCOA3 | |
| Isoquinoline SCHEMBL28860064 | 0.78 | CYP11B2 (0.47) | CYP11B2CYP11B1CYP17A1CYP19A1NCOA3 | |
| SCHEMBL29489123 | 0.78 | CYP2A6 (0.52) | CYP11B2CYP11B1CYP17A1CYP19A1IMPDH2 | |
| SCHEMBL1341822 | 0.78 | CYP2A6 (0.52) | CYP11B2CYP11B1CYP17A1CYP19A1IMPDH2 | |
| SCHEMBL28435230 | 0.77 | MELK (0.63) | MELKCYP11B2CYP11B1CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800909-A | Synthetic method of nitrogen-containing aromatic heterocyclic methylamine | 北京六合宁远医药科技股份有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-110382475-A | NRF2 activator | 比奥根MA公司 | 2019-10-25 | — | — | CN | claimed |
| EP-4615838-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-120091998-A | Substituted bicyclic rings as HSET inhibitors | 默克专利股份公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024258789-A1 | MODULATORS OF CDK2 AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024099898-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| CN-117800909-A | Synthetic method of nitrogen-containing aromatic heterocyclic methylamine | 北京六合宁远医药科技股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1189879-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| CN-1275979-A | Isoquinoline compounds useful as urokinase inhibitors | PFIZER (US) | 2000-12-06 | — | — | CN | disclosed |
| WO-2000071512-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | MELK 936/4885CYP11B2 2223/4885CYP11B1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.